论文部分内容阅读
目的探讨环氧化酶-2(COX-2)和血管内皮因子VEGF在乳腺癌组织中的相关性表达及其临床意义。方法采用免疫组化方法检测60例乳腺癌和30例良性肿瘤组织中COX-2、VEGF的表达情况,并分析乳腺癌生物学行为并判断其与预后的关系。结果乳腺癌组COX-2和VEGF阳性率分别为56%和65%,与对照组比较差异有显著性P<0.01;COX-2表达与VEGF显著相关P<0.05。两者均与乳腺癌预后有关。结论COX-2和VEGF在乳腺癌组织中的表达较高者是影响乳腺癌患者预后的主要原因之一。因此,联合检测COX-2和VEGF对乳腺癌患者判断预后、指导临床有重大意义。
Objective To investigate the expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor VEGF in breast cancer and its clinical significance. Methods Immunohistochemistry was used to detect the expression of COX-2 and VEGF in 60 cases of breast cancer and 30 cases of benign tumor. The biological behavior of breast cancer was analyzed and the relationship between the expression of COX-2 and prognosis was analyzed. Results The positive rates of COX-2 and VEGF in breast cancer were 56% and 65%, respectively, which were significantly different from those in control group (P <0.01). The expression of COX-2 was significantly correlated with VEGF (P <0.05). Both are related to the prognosis of breast cancer. Conclusion The higher expression of COX-2 and VEGF in breast cancer tissue is one of the main reasons that affect the prognosis of breast cancer patients. Therefore, the combined detection of COX-2 and VEGF in breast cancer patients with prognosis, clinical guidance of great significance.